Hurricane Satellite Weather Tracking - View Hurricane Weather Track |
Stop Parking Domain Names Develop Your Domain Names |
|||||
World Alzheimer's Day 2008 Special Report: New Alzheimer Targets Take Center Stage
Los Angeles, CA (PRWEB) September 23, 2008 -- AlzheimerVideoNews.com debuts with a World Alzheimer's Day 2008 Special Report, discussing the most significant developments which occurred in 2008 in the field of Alzheimer's disease research. The new report, available in both a video news report and in print at AlzheimerVideoNews.com (http://www.AlzheimerVideoNews.com), discusses several innovative therapeutics which address emerging new targets in Alzheimer's disease. These new therapeutics have taken center stage in 2008, after the prominent failure of the anti-amyloid investigational drugs tramiprosate(Alzhemed®, Neurochem) and Flurizan® (Myriad Genetics).
The promising new therapeutic agents discussed at ICAD 2008, the world's leading forum on dementia research, and in scientific publications in 2008, included the antihistamine Dimebon® (Medivation, now licensed to Pfizer); Rember®, a reforumulation of methylene blue (TauRX Therapeutics of Singapore); and a novel, off-label method of perispinal administration of etanercept. These agents are all hypothesized to address non-amyloid targets, including the tau tangles found in the brain(Rember®).
Among these agents etanercept is unique, because it was designed to correct an abnormality in the immune system, identified in Alzheimer's disease, which may affect brain function. This abnormality, an excess of the molecule TNF in the cerebrospinal fluid, is hypothesized to interfere with brain cell communication in patients with Alzheimer's disease and related forms of dementia.
AlzheimerVideoNews.com takes a critical look at the most important news in Alzheimer's research. The AlzheimerVideoNews.com website (http://www.AlzheimerVideoNews.com) includes links to further reports and discussion regarding recent developments in Alzheimer's research. AlzheimerVideoNews.com is sponsored by the Institute for Neurological Research, a private medical group, inc. in Los Angeles (http://www.nrimed.com), which has developed the perispinal etanercept anti-TNF strategy for dementia.
References: Doody, R.S., S.I. Gavrilova, M. Sano, R.G. Thomas, P.S. Aisen, S.O. Bachurin, L. Seely, and D. Hung, Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet, 2008. 372(9634): p. 207-15.
Tobinick, E.L. and H. Gross, Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol, 2008. 8(1): p. 27.
###
This press release has been reprinted from PRWEB per the terms and conditions of the copyright notice.
|
MORE ARTICLES:
June 2005: Weather Forecasts for Weather Traders
Hurricane Katrina, A Personal View
Bourbon Orleans New Orleans Hotel Invites Guests to Enjoy Christmas New Orleans Style
Pensacola Lawyer Launches ‘Florida Hurricane Hotline™’ for 2006 Hurricane Season
July 2005: Hurricane Forecasts for Weather Traders
Vino at the View - The Beginning: Wine Tasting with an Unbridled View of Las Vegas
Hurricane Season Easier to Weather with Launch of Generatorstore.com
LegalView Mesothelioma Blog Reports that Asbestos Exposure Slows Hurricane Katrina Cleanup in New Orleans Parish
Hurricane Katrina's Delicious Aftermath in New Orleans Wins an International Award
Leading Tarp Manufacturer Prepares For Major 2008 Hurricane Weather Season
Watch Satellite TV On PC Online Without Viewing Restrictions
Archdiocese of New Orleans Selects Harcourt's Learnia to Monitor Student Progress
Weather Decision Technologies Unveils Automated Weather Warning System for International Airports
New Orleans Hurricane Battle Zone for Virtual Reality Training
Follow the Path to Literacy with Training from Parents as Teachers National Center
|
|||||
| Develop Your Domain Names | Site Map | Home | ||||||